Jointown(SH:600998) Quan Jing Wang·2025-05-08 00:02Group 1 - The core viewpoint of the news is that Jiuzhoutong is focusing on its new product strategy and has shown significant growth in revenue and profit in 2024, with a strong emphasis on brand promotion and marketing capabilities [1][2] - In 2024, Jiuzhoutong's total sales revenue from its general agency brand promotion business (including pharmaceuticals and medical devices) reached 19.267 billion yuan, with a gross profit of 2.16 billion yuan [1] - The company has introduced a total of 2,247 specifications of pharmaceuticals and medical devices, with 52 single products achieving sales exceeding 100 million yuan [1] Group 2 - Jiuzhoutong reported a revenue of 151.81 billion yuan and a net profit attributable to shareholders of 2.507 billion yuan for the year 2024, with a year-on-year revenue growth of 2.58% and a net profit growth of 39.88% [2] - In the first quarter of 2025, the company achieved a revenue of 42.016 billion yuan, representing a year-on-year growth of 3.82%, and a net profit of approximately 970 million yuan, which is an increase of 80.38% compared to the same period last year [2]